TMCI
Get informed when a big investor buys or sells
+ FollowOvervalued by 129.3% based on the discounted cash flow analysis.
| Market cap | $281.55 Million |
|---|---|
| Enterprise Value | $282.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.93 |
| Beta | 1.4 |
| Outstanding Shares | 65,049,844 |
| P/E Ratio | -4.67 |
|---|---|
| PEG | 53.24 |
| Price to Sales | 1.61 |
| Price to Book Ratio | 4.82 |
| Enterprise Value to Revenue | 1.37 |
| Enterprise Value to EBIT | -5.05 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.19 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 646.63% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 55.71%▼ 0.85% |
|---|---|
| Total Invested | $48.30M▼ 44.99% |
| Investors Holding | 117▼ 1.00% |
No data
Based in Ponte Vedra, FL, Treace Medical Concepts, Inc. is a privately-held medical device company focused on advancing the standard of care for the surgical management of bunion deformities. The Company’s patented Lapiplasty® 3D Bunion ...